Compounded Bi-Est Cream Is Not Recommended for This Patient
I do not recommend prescribing compounded Bi-Est cream (80:20 estriol:estradiol) for your 42-year-old perimenopausal patient with low estradiol and regular periods. The FDA has not approved any compounded bioidentical hormone therapy for prevention of chronic diseases, and the safety and effectiveness of these products have not been evaluated through the FDA's drug approval process 1. More importantly, there are no randomized controlled trials demonstrating the benefits or harms of bioidentical hormones for any indication in perimenopausal or postmenopausal women 1.
Key Evidence Against Compounded Bi-Est
Inadequate Estrogen Exposure
Compounded Bi-Est creams deliver significantly lower estrogen levels than FDA-approved transdermal products. A randomized pharmacokinetic trial found that all tested doses of Bi-Est cream (2.0,2.5, and 3.0 mg) produced consistently lower estradiol exposure compared to standard-dose estradiol patches, with statistically significant differences for the 2.0 mg dose (AUC 181 vs. 956; p<0.001) and 2.5 mg dose (AUC 286 vs. 917; p<0.001) 2.
A large retrospective cohort study confirmed that compounded transdermal estradiol creams produce significantly lower urinary estradiol concentrations than FDA-approved patches and gels across all dose ranges (p=0.013 for low dose, p<0.001 for mid dose, p=0.009 for high dose) 3.
Estriol levels remain low even with Bi-Est formulations, failing to contribute meaningfully to therapeutic effect 2.
Lack of Standardization and Quality Control
Compounded preparations lack well-controlled studies examining route of administration, pharmacokinetics, safety, and evidence-based rationale for the mixture and ratios of bioidentical estrogens 4.
There is no established dosing guideline for compounded Bi-Est preparations, and the dose-response relationship is unpredictable 2.
What You Should Prescribe Instead
FDA-Approved Transdermal Estradiol
For perimenopausal women with bothersome symptoms, prescribe FDA-approved transdermal estradiol patches or gels, which have:
- Established pharmacokinetics and predictable dose-response relationships 5, 6
- Regulatory oversight ensuring quality and consistency 1
- Evidence-based dosing guidelines 7
Specific Dosing Approach
Start with a standard licensed dose (e.g., 0.05 mg estradiol patch twice weekly or equivalent gel formulation) 8, 5.
Titrate based on symptom response, recognizing that there is substantial interindividual variation in estradiol absorption (reference interval 54.62-2,050.55 pmol/L in real-world users) 6.
Consider measuring serum estradiol levels if symptoms persist despite dose escalation, as approximately 25% of women using the highest licensed doses have subtherapeutic levels (<200 pmol/L) 6.
Younger women (<50 years) and gel users show greater variance in absorption, requiring more careful dose adjustment 6.
Progestin Protection
Since your patient has regular periods and presumably an intact uterus, she requires progestin protection to prevent endometrial hyperplasia and cancer 1, 9.
Use FDA-approved micronized progesterone (e.g., 100-200 mg orally at bedtime) or a progestin-containing product 7.
Critical Caveats
This Is Not About Disease Prevention
The USPSTF guidelines against hormone therapy apply only to disease prevention in postmenopausal women, not symptom management in perimenopausal women 1.
Your patient is perimenopausal with symptoms (implied by low estradiol), making symptom relief the appropriate indication 1, 7.
Contraindications to Screen For
Before prescribing any estrogen therapy, ensure your patient does not have 8:
- Undiagnosed abnormal genital bleeding
- Known or suspected breast cancer or estrogen-dependent neoplasia
- Active or history of venous thromboembolism or arterial thromboembolic disease
- Known thrombophilic disorders
- Liver dysfunction or disease
- Pregnancy
Monitoring Considerations
Do not rely on FSH or estradiol levels to guide management of menopausal symptoms in routine practice 8.
However, serum estradiol measurement can be helpful to identify women who may benefit from dose adjustment, particularly those with persistent symptoms on standard doses 5, 6.
The bottom line: Compounded Bi-Est cream delivers inadequate and unpredictable estrogen exposure compared to FDA-approved alternatives that have established safety profiles and dosing guidelines. Use FDA-approved transdermal estradiol with appropriate progestin protection instead 1, 2, 3, 7.